Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand, PD-L1, can induce durable anti-tumor response, but can also cause immune-related adverse events (irAEs) (Martins et al., 2019; Hommes et al., 2020). This evidence concerns the gene PDCD1 and neoplasm.